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hTERTall DNA viruses that encode approximately eight genes, and require the host cell
DNA replication machinery for their viral DNA replication. Thus papillomaviruses have evolved strategies to
induce host cell DNA synthesis balanced with strategies to protect the cell from unscheduled replication.
While the papillomavirus E1 and E2 genes are directly involved in viral replication by binding to and
unwinding the origin of replication, the E6 and E7 proteins have auxillary functions that promote
proliferation. As a consequence of disrupting the normal checkpoints that regulate cell cycle entry and
progression, the E6 and E7 proteins play a key role in the oncogenic properties of human papillomaviruses
with a high risk of causing anogenital cancers (HR HPVs). As a consequence, E6 and E7 of HR HPVs are
invariably expressed in cervical cancers. This article will focus on the E6 protein and its numerous activities
including inactivating p53, blocking apoptosis, activating telomerase, disrupting cell adhesion, polarity and
epithelial differentiation, altering transcription and reducing immune recognition.
© 2008 Elsevier Inc. All rights reserved.Structure of E6
All papillomaviruses encode an E6 open reading frame immedi-
ately downstream of the noncoding region (NCR). E6 proteins are
approximately 150 amino acids containing two CX2C-X29-CX2C zinc-
like ﬁngers joined by an interdomain linker of 36 amino acids, ﬂanked
by short amino (N) and carboxy (C) terminal domains of variable
lengths. The E7 protein contains a similarly spaced zinc-like ﬁnger
leading to the hypothesis that the E6 and E7 genes may have arisen
from duplication events of one of these core motifs (Cole and Danos,
1987). A number of papillomavirus E6 and E7 proteins have been
shown to bind zinc through the coordination of the cysteine residues
(Barbosa et al., 1989; Grossman and Laimins,1989). Attempts to obtain
the crystal structure of E6 have been plagued by the tendency of E6 to
form insoluble aggregates. Recently the solution structure of the C-
terminal half of HPV 16E6 was solved by nuclear magnetic resonance
(NMR), and a model for the whole protein was proposed (Fig. 1)
(Nomine et al., 2006). The two zinc ﬁnger domains face each other
symmetrically in a pseudodimeric fashion with the interdomain
forming a helix that contributes to the rigidity of the two domains.
Each domain consists of a three stranded beta sheet (S1, S2, S3) and
two short helices (H1, H2). The N and C terminal domains are of
variable lengths and sequences. The proposed structure indicated that
many of the mutations that have been made to map functions of E6
likely disrupted the overall structure, rather than speciﬁc protein–
protein interactions.ll rights reserved.Although E6 may dimerize at high salt and protein concentrations,
it is thought to be monomeric at physiologic conditions (Lipari et al.,
2001). It has been difﬁcult to study the expression of endogenous E6
proteins as they are expressed at low levels and few sensitive
antibodies exist, however E6 is thought to be largely nuclear, though
some fraction of E6may also be cytoplasmic (Lowy and Howley, 2001).
Spliced isoforms have been reported for the high risk E6 genes, that
would give rise to truncated E6 proteins denoted as E6⁎, encoding
residues 1–41 of 16E6 (Pim and Banks, 1999). E6⁎ inactivates the
functions of full-length E6, which is proposed to be due to its ability to
bind to the interface of the N- and C-terminal halves of E6 (Nomine
et al., 2006). No enzymatic activities have been reported for E6, and
although the HR E6 proteins have been reported to bind speciﬁcally to
four-way DNA junctions (Ristriani et al., 2001), most of the activities of
E6 are thought to be mediated by protein–protein interactions. A
summary of the interactions of HR HPV E6 proteins with other
proteins and the pathways they impinge upon are shown in Fig. 2.
E6 binding motifs
The ﬁrst protein that was shown to interact with E6 was E6
associated protein (E6AP), an E3 ubiquitin ligase (Huibregtse et al.,
1991; Scheffner et al., 1993). The ubiquitin cascade functions to target
proteins for proteasomal degradation by means of adding multiple
ubiquitin monomers to the protein destined to be destroyed. E1
proteins activate the ubiquitin monomers that are subsequently
transferred by E2 conjugating enzymes to an E3 ubiquitin ligase,
which confers target speciﬁcity (for review see Hershko and Ciechan-
over, 1992). E6AP is the founding member of the HECT-domain family
Fig. 1. The pseudodimeric model of E6 (taken from Nomine et al., 2006). (A) E6N model and E6C structure positioned symmetrically with exposed hydrophobic patches facing each
other. (B) Proposed pseudodimeric arrangement of E6N and E6C. The gray closed line indicates the DNA binding region of E6C, mapped in the present work. (C) Contact map of
hydrophobic residues involved in the interface of the pseudodimeric model. (D) Position of the three ﬂanking regions not predicted by the model.(E) A view of the core model
highlighting surface residues conserved in all E6 proteins. Previously mutated residues are indicated with underlined red labels.
Fig. 2. Binding partners of E6. E6 alters numerous cellular pathways through the binding
of other proteins.
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E6AP C-terminal (HECT) domain involved in ubiquitination of bound
substrates, and divergent N-termini that mediate substrate speciﬁcity
(Schwarz et al., 1998). E6AP forms a complex with both E6 and target
proteins leading to ubiquitination of the target protein and subse-
quent proteasome mediated degradation (Scheffner et al., 1993). The
most well studied E6/E6AP target is the p53 tumor suppressor
(discussed below), though other proteins are also targeted by this
complex. Numerous studies have identiﬁed residues of the E6 protein
that diminishes binding to E6AP (Crook et al., 1991a; Gewin et al.,
2004; Liu et al., 1999b), but recently most of these mutations have
been predicted to disrupt the global integrity of E6 (Nomine et al.,
2006). Moreover, mutations of numerous surface exposed residues of
E6 did not eliminate its binding to E6AP. However, the motif on E6AP
that binds E6 has been extensively characterized (Be et al., 2001; Chen
et al., 1998; Elston et al., 1998) and is referred to as an LXXLL motif. A
number of other proteins also bind to E6 by way of LXXLL motif
including, ERC-55 (E6BP), IRF3, paxillin and tuberin (Chen et al., 1998;
Elston et al., 1998; Ronco et al., 1998; Tong and Howley, 1997). These
motifs are leucine-rich amphipathic helices with limited substitution
of hydrophobic residues for leucines and at least one negative chargein an X position. The sequence of E6AP that interacts with E6 is
ELQELLGE. Binding to proteins with an LXXLL motif is a conserved
property of the E6 proteins of numerous papillomaviruses, as E6AP
binds to both high and low risk genus alpha HPVs, at least some genus
326 Minireviewbeta HPVs and bovine papillomavirus type 1 (Bedard et al., 2008; Chen
et al., 1998; Kuballa et al., 2007).
HR HPV E6 proteins all have a motif designated as S/TXV at their C-
termini. This motif on the E6 protein mediates binding to speciﬁc
domains on cellular proteins known as PDZ proteins. PDZ domains are
approximately 90 amino acid stretches found in a wide variety of
proteins and are named after the ﬁrst letters of three proteins which
were ﬁrst discovered to share the domain; post synaptic density
protein (PSD95), Drosophila disc large tumor suppressor (DlgA), and
zonula occludens-1 protein (ZO-1). Among the PDZ proteins reported
to bind E6 are hDlg1 and hDlg4, human homologs of Dlg (Kiyono et al.,
1997; Lee et al., 1997); hScrib, a homolog of the Drosophilia scribble
protein (Nakagawa and Huibregtse, 2000); MAGI 1, MAGI 2 and MAGI
3,Membrane Associated Guanylate kinase homology proteins with an
Inverted domain structure (Glaunsinger et al., 2000; Thomas et al.,
2001); MUPP1, a multi PDZ protein (Lee et al., 2000); and PTPN3, a
membrane associated tyrosine phosphatase (Jing et al., 2007; Spanos
et al., 2008b). Mutational analyses have demonstrated the importance
of the S/TXV motif in binding, but it is possible that other residues of
E6 also bind and confer speciﬁcity for which PDZ proteins and which
PDZ domains are bound. The concurrent binding of E6 to E6AP and to
PDZ proteins can target the PDZ proteins for degradation, though
other ubiquitin ligases have also been implicated (Grm and Banks,
2004; Sterlinko et al., 2004).
Other proteins such as p53, Bak, p300/CBP, hADA3, NFX1, Gps2,
FADD, and procaspase 8 have been reported to bind various E6
proteins, but they lack both LXXLL and PDZ domains (Degenhardt and
Silverstein, 2001b; Filippova et al., 2007; Filippova et al., 2004; Gewin
et al., 2004; Kumar et al., 2002; Patel et al., 1999; Thomas and Banks,
1999; Zimmermann et al., 2000). They may bind to E6 through as yet
undeﬁned motifs, or indirectly through binding to E6AP or other E6
associated proteins.
Inactivation of p53
One of the most well-studied interacting proteins of E6 is the p53
tumor suppressor, a DNA site-speciﬁc transcription factor, and one of
the key signaling coordinators in the cell following genotoxic or
cytotoxic stress (for review see Murray-Zmijewski et al., 2008).
Normally present in low levels and transcriptionally inactive, cellular
damage triggers an increase in p53 protein levels and activation via
post-translational modiﬁcations. Once activated, p53 functions to
initiate pathways for DNA repair, cell cycle arrest and/or apoptosis,
based upon the type and extent of damage. The importance of p53 in
orchestrating the cellular response to cytotoxic agents is exempliﬁed
by the observation that approximately one-half of all human cancers
harbor mutations in the p53 gene. These mutations impair the ability
of p53 to trigger the appropriate signaling pathways to repair the
damage or trigger cell death in cases where the damage is beyond
repair. This in turn allows for replication of damaged DNA, and
survival of cells with deleterious mutations that would normally be
eliminated.
Importantly, in addition to genotoxic and cytotoxic damage, p53 is
also activated upon improper stimulation of DNA synthesis, such as
that induced by HPV infection. Both HR and LR HPVs infect cells in the
basal layer of the epithelium, however viral replication occurs only in
differentiating cells—which would have normally exited the cell cycle
and turned off their cellular DNA synthesis machinery (Doorbar et al.,
1997). HPVs must therefore stimulate DNA synthesis in these cells,
while concomitantly inhibiting the normal cellular response of
activating p53. Importantly, unlike most other cancer cell types,
cervical cancers generally harbor wild-type p53 (Crook et al., 1991b;
Scheffner et al., 1991). HPVs have evolved a number of mechanisms to
block p53 function in the infected cell through the actions of the E6
oncoprotein. In this way our understanding of E6 highlights the
functions of p53 in normal cells, and demonstrates themechanisms bywhich a regulatory checkpoint can be countered during viral infection
and/or cancer progression via protein degradation, mislocalization
and modiﬁcation.
The principle mechanism by which HR HPVs inactivate p53 is by
inducing its degradation through the ubiquitin–proteasome pathway
(Scheffner et al., 1990). Normally p53 protein levels are regulated by
the Mdm2 E3 ubiquitin ligase (Honda et al., 1997). However Mdm2-
mediated degradation of p53 is inhibited during viral infection and
other stress conditions, allowing for stabilization of p53 protein levels
and subsequent activation (for review see Ashcroft and Vousden,
1999). Instead, HR HPV E6 induces p53 degradation by forming a
complex with another E3 ubiquitin ligase, E6AP (Huibregtse et al.,
1991, 1993a; Scheffner et al., 1993).
E6AP per se, is unable to bind p53 and induce its degradation.
Instead, E6 must ﬁrst bind to the N-terminal substrate recognition
domain of E6AP before p53 can be bound and ubiquitinated
(Huibregtse et al., 1993a, 1993b). Interestingly, both HR and LR HPV
E6 proteins have been shown to interact with p53, however they differ
with respect to the domains of p53 with which they interact. While
bothHR and LR E6 proteins can bind to the p53 C-terminus, only HR E6
proteins are capable of binding to the core region of p53. It is this
binding of the core region that is required for p53 degradation by HR
E6 (Crook et al., 1991a; Li and Cofﬁno, 1996).
Although stimulation of p53 degradation mediates a considerable
block to p53 function, not all of the p53 within E6-expressing cells is
degraded (Cooper et al., 1993; Lechner et al., 1992; Lie et al., 1999;
Mantovani and Banks, 1999). Moreover, as mentioned above, the LR
genus alpha HPV, and the genus beta HPV E6 proteins do not degrade
p53, and therefore have evolved different mechanisms of circumvent-
ing p53 growth suppression. In part, infection with these papilloma-
viruses may induce a p53 response less robustly than the HR HPVs.
Additionally, some assays have shown that expression of both HR and
LR E6 proteins can abolish p53-mediated transcriptional activity
(Crook et al., 1994; Giampieri et al., 2004; Lechner et al., 1992; Mietz et
al., 1992). It has been shown that E6 can mediate these effects through
a number of mechanisms, including inhibition of p53 binding,
aberrant p53 localization, and post-translational modiﬁcations of
the p53 protein.
First, it has been shown that E6 interactionwith p53 can inhibit the
binding of p53 to its site-speciﬁc DNA sequences (Lechner and Laimins,
1994; Thomas et al., 1995). The level of inhibition was found to
correlate with the afﬁnity that each E6 protein has for p53; thus 16E6
shows the highest level of site speciﬁc binding inhibition, 31E6 and
18E6 show intermediate levels of inhibition, and 11E6 shows the least,
albeit still detectable inhibitory effect (Lechner and Laimins, 1994).
Moreover, it was later shown that E6 associationwith p53 can induce a
conformational change in the p53 protein, which in turn leads to an
inhibition of p53 binding to DNA, or a dissociation between p53–DNA
complexes that have already been formed (Thomas et al., 1995).
Importantly, these inhibitory effects were shown to correlate with the
ability of different E6 proteins to inhibit p53 transactivation, and were
shown to be independent of E6/E6AP-mediated p53 degradation.
The second proposed mechanism by which E6 may be able to
inhibit p53 signaling independent of protein degradation is by means
of sequestration of p53 in the cytoplasm. This has beenhypothesized to
be a result of either masking of the nuclear localization signal (NLS) on
the p53C-terminus due to E6bindingof p53, or an enhancementof p53
nuclear export (seeMantovani and Banks, 2001). As both HR and LR E6
proteins are able to bind to the C-terminus of p53,masking the p53NLS
is an attractive possibility. Evidence for E6-mediatedmislocalization of
p53 has been demonstrated from experiments using cervical cell lines
in which E6-mediated p53 degradation was blocked. In these cells,
even thoughp53 levels returned to normal, correct nuclear localization
of p53 was perturbed (Mantovani and Banks, 1999). Further investiga-
tionwill be required to determine if either of these mechanisms play a
role in E6-mediated mislocalization of p53.
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abrogation of the transactivation of p53 responsive genes via
interaction with either the CBP/p300 (Patel et al., 1999; Zimmermann
et al., 2000) or hADA3 (Kumar et al., 2002) histone acetyltransferases.
Following DNA damage, p300 is known to acetylate p53, thus
enhancing its ability to bind to speciﬁc DNA sequences in the
promoters of p53-responsive genes, and in turn upregulating their
transcription (Barlev et al., 2001; Gu and Roeder, 1997; Ito et al., 2001;
Liu et al., 1999a; Yuan et al., 1999). The E6 proteins have been shown to
bind to p300, and this interaction inhibits p53 acetylation at p300-
dependent sites, leading to decreased expression from a p53
responsive luciferase reporter (Patel et al., 1999; Zimmermann et al.,
2000). Both HR and LR E6 proteins have been shown to bind to p300,
although the HR E6 proteins appear to bind with a higher afﬁnity. In-
vivo studies have reported that only the HR E6 proteins prevent p300
transactivation of p53 responsive genes (Patel et al., 1999; Zimmer-
mann et al., 2000); however an in-vitro analysis using chromatinized
templates demonstrated that LR HPV 11E6 was also capable of
inhibiting p53 transactivation (Thomas and Chiang, 2005). This study
also demonstrated that while E6 mutants deﬁcient in E6AP binding
were capable of inhibiting p53, mutants defective in binding to either
p53 or p300 were unable to elicit this response. Thus a complex
between E6, p53 and p300 appears to be required to block
transactivation.
Similarly, HR E6 proteins are also able to block p53 activation by
interacting with another histone acetyltransferasere, hADA3 (Kumar
et al., 2002). hADA3 is the human homolog of the yeast transcriptional
activator yADA3, which functions as an essential component of the
ADA transcriptional coactivator complex (Pina et al., 1993). However,
unlike with p300, E6 interaction with hADA3 results in hADA3
degradation (Kumar et al., 2002). This degradation has been shown to
abrogate both p53- and retinoic X receptor (RXR) alpha-mediated
transactivation (Kumar et al., 2002; Zeng et al., 2002).
Finally, recent evidence suggests that E6 may also inhibit p53
activation by blocking the p14/ARF pathway (Shamanin and Andro-
phy, 2004; Shamanin et al., 2008). Following most cellular stresses,
p53 is activated due to cellular signals that prevent its interactionwith
and degradation by Mdm2 (see above). However, p53 can also be
activated during “oncogenic stress” by a mechanism involving direct
inhibition of Mdm2 ubiquitin ligase activity through its association
with ARF (Matheu et al., 2008). 16E6 has been shown to inhibit p14/
ARF dependent activation of p53 without inactivation of the p53-
dependent DNA damage response, and in a manner that is not
dependent on E6-mediated p53 degradation (Shamanin and Andro-
phy, 2004). Interestingly, one mechanism by which this has been
proposed to be facilitated is through the degradation of hADA3
(Shamanin et al., 2008).
Modulation of G-protein signaling
As described above, E6 is able to modulate transcription of p53-
dependent genes either by degradation of p53 or via interaction with
the p300 and hADA3 transactivators. In addition, yeast two-hybrid
experiments from a number of groups have demonstrated that E6 is
able to modulate transcription from other cellular signaling pathways
as well, highlighting the ability of the E6 oncoprotein to act as a
diverse modulator of host cell signaling. With respect to G-protein
signaling, E6 has been shown to interact with three different proteins.
First, HR E6 was shown to bind and degrade a novel protein termed
E6-targeted protein 1 (E6TP1) in an E6AP dependent manner (Gao
et al., 2002; Gao et al., 1999; Lee, Wooldridge, and Laimins, 2007).
E6TP1 has homology to GTPase activating proteins (GAPs) for Rap (Gao
et al., 1999), and recent experiments demonstrated that E6TP1 does
indeed harbor GAP activity for Rap1 and Rap2 (Singh et al., 2003).
Importantly, E6 mediated degradation of E6TP1 enhances the GTP-
loading of RAP, thus supporting a role for the RAP small G-protienpathway in E6-mediated oncogenesis (Singh et al., 2003). Another
protein with GAP activity, tuberin, was also shown to be bound and
degraded by E6 (Lu et al., 2004; Zheng et al., 2008). Tuberin functions
in the harmatin–tuberin complex, which exhibits GAP activity toward
the small G-protein Rheb, and the complex is a critical negative
regulator of mTOR signaling (reviewed in Huang and Manning, 2008).
As this pathway is an important mediator of cell growth, it highlights
yet another mechanism by which E6 can modulate the regulation of
such processes. Finally, E6 from both HR and LR HPVs was shown to
bind and degrade Gps2 (Degenhardt and Silverstein, 2001b). Gps2 is
involved in suppressing G-protein mediated signaling pathways
(Spain et al., 1996), c-Jun N-terminal kinase activity (Jin et al., 1997),
and known to stimulate transcriptional activation by the BPV1 E2
protein (Breiding et al., 1997). As seen with BPV, Gps2 was found to
stimulate transcription from HPV promoters (Degenhardt and
Silverstein, 2001b). Moreover, HR (but not LR) E6-mediated degrada-
tion of Gps2 was shown to suppress this transactivation of the HPV
early promoter. As Gps2 is known to interact with and positively
regulate p300 (Peng et al., 2000), the implications of Gps2 degradation
may extend beyond that of transcriptional control of HPV encoded
genes, however this remains to be determined.
Modulation of immune recognition
E6 has also been shown to modulate transcription of genes whose
protein products are involved in innate immunity. HR E6 has been
shown to interact with two proteins that are part of the innate
immune response to viral infection; Interferon regulatory factor-3
(IFR-3) (Ronco et al., 1998) and Toll-like receptor 9 (TLR9) (Hasan et al.,
2007). IRF-3 becomes activated by dsRNA or viral infection, and this
activation leads to transcription of Interferon-β (IFN-β) (for review see
Hiscott, 2007). 16E6 interaction with IRF-3 has been shown to inhibit
its transactivation ability, and thus prevents the induction of IFN-β
following viral infection (Ronco et al., 1998). TLR9 becomes activated
by viral or bacterial dsDNA derived CpG motifs, and induces cytokine
production as a means to defend the cell against the invading
organism (Muller et al., 2008). Exogenous expression of 16E6/E7 has
been shown to inhibit TLR9 transcription, leading to a functional loss
of TLR9 signaling pathways within the cell (Hasan et al., 2007). Similar
results were seen in the HPV 16 positive cervical carcinoma cell lines
CaSki, SiHa and HeLa, demonstrating that this may indeed contribute
to HPV-mediated carcinogenesis.
Blocking apoptosis
One of the main consequences of E6 degrading or blocking p53
function is to inhibit apoptotic signaling that would otherwise
eliminate the HPV infected cell. However, p53 independent apoptotic
signals can also be employed to eliminate abnormal cells, and E6 has
been shown to block apoptosis in cells and mice lacking p53 (Pan and
Griep, 1995; Steller et al., 1996). There are two major apoptotic
pathways that can be triggered by different stresses — the extrinsic
pathway, and the intrinsic pathway (Fig. 3). Interestingly, the E6
protein has been shown to disrupt both pathways to facilitate a
cytoprotective environment and prevent cell death, thus highlighting
the critical signaling events that a cell undergoes following exogenous
or endogenous stress.
The extrinsic apoptotic signaling pathway can be induced during
viral infection as part of the host response, and is triggered by
extracellular signals that induce the activation of “death receptors” on
the cell surface (for review see Gewies, 2003). These receptors are
members of the tumor necrosis factor receptor (TNFR) family and
include TNF receptor 1 (TNFR-1), Fas/CD95 and the TNF-related
apoptosis inducing ligand (TRAIL) receptors DR-4 and DR-5. Upon
binding to their cognate ligand (TNF, Fas-L or TRAIL), these receptors
trimerize and recruit adapter molecules such as FADD, TRADD and
Fig. 3. Extrinsic and intrinsic apoptotic pathways. The extrinsic pathway is activated through trimerization of death receptors, followed by recruitment of adapter molecules and pro-
caspase 8 to form the DISC. Subsequent cleavage of caspase 8 leads to cleavage of downstream executioner caspases, caspase 3 and caspase 7, and subsequent cell death. E6 can block
death receptor association with adapter molecules (1) and can induce the degradation of certain adapter molecules as well as caspase 8 (2). Activation of the intrinsic pathway by
“intrinsic” cell stresses leads to the formation of pores in the mitochondrial membrane, and subsequent release of mitochondrial inner membrane proteins into the cytosol. These
proteins, alongwith pro-caspase 9 form the apoptosome, which cleaves caspase 9. Activated caspase 9 then goes on to cleave the downstream executioner caspases 3 and 7, leading to
cell death. E6 has been shown to degrade Bak, and thus block the release of the mitochondrial inner membrane proteins into the cytosol (3). E6 is also able to inhibit IAPs and thus
block the apoptosome and cleavage of the exectutioner caspases (4).
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death domains (DD), thus forming the death inducing signaling
complex (DISC). The DISC is involved in activating caspase 8, which in
turn cleaves and activates downstream executioner caspases (caspase 3
and caspase 7). The executioner caspases target and cleave downstream
substrates such as poly(ADP-ribose) polymerase (PARP) and Lamin B.
E6 has been shown to inhibit extrinsic apoptotic signaling at each
of the early stages, by interacting with TNFR-1, FADD and caspase-8.
16E6 was shown to directly bind to the death receptor TNFR-1, an
interaction that inhibited TNFR-1 association with the TNF R1-
associated death domain (TRADD) adapter molecule, and blocked
TNFR-1 DD mediated apoptosis (Filippova et al., 2002) (Fig. 3 #1).
Importantly, 16E6 has also been shown to block apoptosis normally
triggered by TNF, the cognate ligand for TNFR-1 (Duerksen-Hughes et
al., 1999). In addition to the TNF pathway, it has also been shown that
16E6 is capable of inhibiting apoptosis stimulated by both the Fas and
the TRAIL pathways. This inhibition is mediated by E6 binding to and
degradation of both the FADD adapter protein and the effector
caspase, caspase-8 (Filippova, Parkhurst, and Duerksen-Hughes, 2004;
Garnett et al., 2006) (Fig. 3 #2). As FADD and caspase-8 are key
components to apoptotic signaling through all of the death receptors,
this mechanism of cytoprotection demonstrates how the E6 oncopro-
tein is able to exploit one or two proteins as a means to block multiple
signaling pathways. Importantly, these effects were all seen using the
HR 16E6 oncoprotein, and it is unknown whether LR or genus beta
HPV E6 proteins function in a similar manner with respect to blocking
extrinsic apoptotic pathways. As the binding of FADD is not dependent
on the conserved PDZ domain of HR E6, but rather a novel domain
(Tungteakkhun et al., 2008), it is possible that other E6 proteins may
inhibit these extrinsic pathways.
The intrinsic apoptotic pathway is involved in sensing apoptotic
signals that originate from within the cell, such as DNA damage,oxidative stress, starvation and those mediated by chemotherapeutic
drugs (Gewies, 2003; Kaufmann and Earnshaw, 2000; Wang, 2001).
These stresses activate a number of pathways that converge on the
mitochondria, which act as a hub to sense the balance of pro- and anti-
apoptotic signals and facilitate downstream apoptotic signaling when
this balance is upset. When the cell senses intrinsic stress, pro-
apoptotic BH3-only proteins become activated and abrogate the
function of anti-apoptotic proteins. This allows for the formation of
pores in themitochondrial membrane comprised of pro-apoptotic Bax
or Bak, and subsequent release of mitochondrial inner membrane
proteins such as cytochrome c, apoptosis inducing factor (AIF),
endonuclease G, Smac/Diablo and Htr/Omi. These mitochondrial
proteins form the “apoptosome”, an apoptotic signaling complex
that, like the DISC from the extrinsic pathway, result in the cleavage of
caspase 3 and caspase 7, and ultimately cell death.
The E6 oncoproteins from both HR and LR HPVs have been found to
block intrinsic apoptotic signaling primarily by interacting with only
one protein — Bak (Fig. 3 #3). Both HR and LR E6 proteins from genus
alpha and beta HPVs have been shown to bind Bak, and induce its
proteasomal-dependent degradation (Jackson et al., 2000; Thomas
and Banks, 1998; Thomas and Banks, 1999; Underbrink et al., 2008).
While E6AP has been shown to play a role in Bak degradation (Thomas
and Banks, 1998; Underbrink et al., 2008), it has also been proposed
that this may not be a universal mechanism for all of the HPV types
(Simmonds and Storey, 2008), thus the involvement of other E3
ubiquitin ligases in this process is an area of interest. Whether Bak
degradation is constitutive or induced following cell stress is also a
topic of controversy. Recent evidence has shown that Bak degradation
is not constitutive, but rather occurs only after apoptotic signals have
been initiated, indicating that a Bak conformational change and/or
dissociation from its anti-apoptotic partner MCL-1 may be necessary
for its interaction with E6 and E6AP (Jackson et al., 2000; Underbrink
329Minireviewet al., 2008). Other studies have found constitutively lower levels of
total Bak protein in E6 expressing cells (Du et al., 2004; Struijk et al.,
2008; Thomas and Banks, 1998; Thomas and Banks, 1999). Regardless
of whether Bak degradation is constitutive or induced, the overall
effect has been shown to be a block the release of cytochrome c, AIF
and Omi from the mitochondria, preservation of mitochondrial
integrity, and disruption of the cleavage of effector caspases (Leverrier
et al., 2007; Underbrink et al., 2008). A ﬁnal area of controversy
surrounds the ability of E6 to perturb other intrinsic apoptotic
mediators. One study has shown that 16E6 expression leads to an
increase in the anti-apoptotic Bcl-2 protein (Du et al., 2004). Another
group demonstrated that 5E6 and 8E6 expression leads to a decrease
in the levels of Bax protein expression (Struijk et al., 2008). A third
study examined the levels of Noxa, Puma, Bcl-xL, Mcl-1, Bcl-2 and Bax,
and found none of these intrinsic apoptotic signaling proteins to be
perturbed in E6-expressing cells (Underbrink et al., 2008).
Importantly the extrinsic and intrinsic pathways are not isolated.
Caspase 8 can be activated during intrinsic apoptotic signaling via an
ampliﬁcation loop mediated by caspases 3 and 7. Likewise, mitochon-
drial signaling can be triggered during activation of the extrinsic
cascade, via caspase 8 mediated cleavage of the BH3-only protein Bid.
These mechanisms are thought to help amplify apoptotic signaling
once signals have been detected (for review see Gewies, 2003). Thus,
by E6 targeting both intrinsic and extrinsic signaling, it not only
protects an infected cell from multiple apoptotic stimuli, but also
protects the cell from cross activation between these two pathways.
Moreover, E6 has been shown to interact with proteins that are
involved in apoptotic signaling at the crossroads where the intrinsic
and extrinsic pathways join, downstream of the effector caspases. HPV
16E6 has been shown to upregulate the expression of two inhibitor of
apoptosis (IAP) proteins, c-IAP2 (James et al., 2006b; Yuan et al., 2005)
and survivin (Borbely et al., 2006) (Fig. 3 #4). IAPs are proteins that can
bind to and inactivate the executioner caspases, caspase-3 and
caspase-7 (see Gewies, 2003). c-IAP2 upregulation appears to be
due to E6 mediated activation of NF kappa B, a well known anti-
apoptotic signaling molecule (James et al., 2006b). As NF kappa B has
other well known cytoprotective effects, it is possible that other NF
kappa B responsive proteins play a role in E6 mediated cytoprotection
as well. Finally, 16E6 has also been reported to bind to and degrade c-
Myc in a proteasomal and E6AP dependent manner (Gross-Mesilaty
et al., 1998). However other studies have reported increased levels of
c-Myc in E6 expressing cells (McMurray and McCance, 2003) or no
change in the level of c-Myc (Gewin and Galloway, 2001; Veldman
et al., 2001), thus the overall role that c-Myc may play in E6-mediated
cytoprotection is uncertain.
Induction of telomerase activity
Expression of HR HPV E6 protein in concert with HR HPV E7
protein can immortalize epithelial cells in culture (Hawley-Nelson
et al., 1989; Munger et al., 1989), and one critical cellular target is
telomerase (Kiyono et al., 1998; Klingelhutz et al., 1996; Veldman et al.,
2003). Understanding how E6 affects telomerase shines a spotlight on
a critical target for oncogenic progression and avoidance of cellular
senescence.
As linear DNA is replicated in each cell division, approximately
150–200 nucleotides at the 3′ end of chromosomes is lost due to the
directional ampliﬁcation of DNA (Levy et al., 1992). To avoid losing
critical genetic information on chromosomes and to prevent recom-
bination at the termini, their ends are capped with repetitive
telomeric DNA approximately 10–12 kb in length and proteins
collectively named shelterin (de Lange, 2005). The protection of
genetic material within chromosomes is important, as is the folding of
telomeric DNA into a T-loop (Grifﬁth et al., 1999) to avoid DNA damage
signals and senescence or apoptosis signals (Karlseder et al., 1999). As
telomeres shorten with each cell division, the age of a cell is clearlymarked in time (Allsopp et al., 1992; Harley et al., 1990). When
telomeres become critically shortened, cells are signaled to senesce
(Hayﬂick, 1965; Hayﬂick and Moorhead, 1961); if they do not, there
can be catastrophic DNA damage, including anaphase bridges and
double strand DNA breaks.
Telomerase is a ribonucleoprotein that extends to telomeric ends
of linear chromosomes in eukaryotes. Normally quiescent in somatic
cells, telomerase is active in stem cells and during embryonic
development. The RNA component of telomerase, TERC, is the
template for the repetitive DNA in telomeres, TTAGGG in humans.
Dyskerin is an additional key protein subunit of telomerase (Cohen
et al., 2007), and hTERT is the catalytic subunit of telomerase (Cohen
et al., 2007; Kilian et al., 1997; Nakamura et al., 1997). The expression
level of hTERT is proportionate to the enzymatic activity of telomerase
in cells, and in the majority of immortalized cells and cancers hTERT is
detected (Bryan and Cech, 1999; Meyerson et al., 1997; Shay and
Bacchetti, 1997). If telomerase is not active in immortalized cells or in
cancers, telomeric DNA is extended using the alternative lengthening
of telomeres (ALT) pathway of homologous end joining (Bryan et al.,
1995; Neumann and Reddel, 2002). So, the protection of telomeric
DNA to avoid signals of cellular senescence or catastrophic chromo-
somal damage is key to cellular dysregulation in cancers and must be
controlled in normal, differentiated somatic cells.
In 1996 it was found that HR HPV E6 protein could activate
telomerase in epithelial cells (Klingelhutz et al., 1996), and less than
ten years later it was found that E6AP was critical for hTERT regulation
by E6 (Gewin et al., 2004; Liu et al., 2005). HR E6 binds the
endogenous E6AP protein and utilizes it in its activation of hTERT
and telomerase (Gewin et al., 2004; James et al., 2006a; Klingelhutz
et al., 1996). Knockdown of E6AP decreases the telomerase activity
triggered by HPV 16E6, as well as genus beta HPV E6 types 38 and 8
(Bedard et al., 2008; Gewin et al., 2004). In one study, mutants of HPV
16E6 that cannot bind E6AP, when expressed in epithelial cells, were
also unable to induce hTERT transcription (Gewin and Galloway,
2001), however, another study using E6 mutants did not ﬁnd a
requirement for E6AP in hTERT induction (Sekaric et al., 2008).
The oncogene c-Myc has been shown to activate hTERT transcrip-
tion (Wang et al., 1998; Wu et al., 1999). The heterodimer c-Myc/Max
binds two E-box sequences in the core proximal promoter of hTERT
(Cong et al., 1999; Lebel et al., 2007; Oh et al., 1999; Oh et al., 2001;
Takakura et al., 1999) (Fig. 4). The HR E6 protein requires the two
proximal E-box sequences to activate hTERT, as mutations in the E-box
sequence blunts the activation of hTERT by E6 in luciferase assays
(Gewin and Galloway, 2001; Liu et al., 2005; Oh et al., 2001; Veldman
et al., 2001). In vivo, E6, c-Myc, and E6AP are found at the hTERT
promoter (Liu et al., 2005; Veldman et al., 2003), and although there is
no strong evidence for signiﬁcant total increases in protein levels of c-
Myc nor differences in c-Myc levels at the hTERT promoter with E6
expression in keratinocytes (Gewin and Galloway, 2001; Veldman
et al., 2001; Veldman et al., 2003; Xu et al., 2008), c-Myc is important
in HPV-associated and non-HPV associated activation of hTERT. The
interaction of HPV E6 with E6AP and c-Myc helps deﬁne the role of
c-Myc in hTERT activation in keratinocytes and differentiate the
regulation of hTERT in keratinocytes and ﬁbroblasts.
Upstream stimulatory factors (USF1 and USF2) also bind to E-box
sites and disrupt binding of c-Myc/Max (McMurray and McCance,
2003) (Fig. 4). Although USFs bind with less afﬁnity to E-boxes, USF1
and USF2 are more abundant than cMyc/Max and can compete for
these sites. USF1 and USF2 have been reported to occupy the hTERT
promoter in keratinocytes, and with E6 expression the amount of
USF1 and USF2 at the promoter is reduced (McMurray and McCance,
2003).
GC-rich sequences are founds throughout the hTERT promoter, and
Sp1 binds to ﬁve GC-rich sites ﬂanked by the two critical E-boxes (Oh,
Kyo, and Laimins, 2001; Takakura et al., 1999) (Fig. 4). Mutations
within these sites reduce the basal expression detected from the
Fig. 4. Model of the hTERT promoter. The catalytic subunit of telomerase, hTERT, is regulated at its core promoter by cis elements that include X1 boxes, E boxes, and GC-rich
sequences. Repressors (shown above the promoter as rectangles) include USF1 and 2, which bind to E-boxes, and NFX1–91, which binds to the downstream X1 box sequence and
recruits histone deacetylase activity through mSin3A. Activators (shown below the promoter as ovals) include the c-Myc/Max heterodimer, which binds to E box sequences and
activates hTERT expression, Sp1, which binds to GC-rich sequences, and histone acetyltransferases, which increase acetylated histones at the hTERT promoter. E6/E6AP affects all of
these repressors and activators. NFX1–123 with cytoplasmic poly(A) binding proteins (PABPCs) work in concert with E6/E6AP to augment hTERT activation.
330 MinireviewhTERT promoter, and the increases in hTERT promoter driven
expression are seen in HPV E6 cells (Oh et al., 2001). Therefore, the
effects of HPV E6 on hTERT expression point to an additional
transcriptional activator of hTERT found commonly in keratinocytes
and recruited by HPV E6 for its activation of telomerase.
Transcriptional activators and RNA polymerases all require access
to their DNA sequences, like c-Myc/Max to their E-boxes and Sp1 to its
GC-rich sites. Acetylation of histones on which DNA is wound opens
the structure of chromatin to these proteins. HPV E6 induces histone
acetylation at the hTERT promoter, and this acetylation depends on
E6AP (James, Lee, and Klingelhutz, 2006a; Xu et al., 2008) (Fig. 4).
With continued passage of HPV E6 cells in culture, the acetylation of
the hTERT promoter increases, and knockdown of E6AP reduces this
acetylation (James et al., 2006a). Thus HPV E6 with E6AP adds to the
evidence of direct transcriptional gene regulation through transcrip-
tional activators or repressors binding to cis elements in promoters, as
well as epigenetic regulation of gene expression, all through its effect
on hTERT.
As E6/E6AP targets p53 for polyubiquitination and degradation, it
also was hypothesized that E6/E6AP may target a yet unknown
transcriptional repressor at the hTERT promoter for polyubiquitina-
tion and degradation. In 2004, NFX1–91 was identiﬁed as a
transcriptional repressor of hTERT in a yeast two hybrid screen with
HPV 16E6 and E6AP (Gewin et al., 2004) (Fig. 4). NFX1, or nuclear
factor binds to the X1 box, was originally identiﬁed as an MHC class II
gene repressor (Song et al., 1994). Two splice variant isoforms are
expressed in epithelial cells, with NFX1–91 referring to its kiloDalton
mass. In keratinocytes, NFX1–91 binds to a X1 box sequence in the
hTERT promoter, recruiting the transcriptional co-repressor mSin3A
and histone deacetylase activity to shut off hTERTexpression (Xu et al.,
2008). The protein–protein interaction of NFX1–91 with the hetero-
dimer HPV E6/E6AP identiﬁed a new endogenous transcriptional
repressor of hTERT important in the regulation of telomerase in
epithelial cells.Like p53, NFX1–91 is polyubiquitinated and targeted for degrada-
tion by 16E6/E6AP. The level of NFX1–91 in HPV 16E6 expressing cells
is reduced, as is its occupancy at the hTERT promoter (Gewin et al.,
2004; Xu et al., 2008). Concomitantly, histone acetylation increases at
the hTERT promoter, though the acetylase has yet to be identiﬁed (Xu
et al., 2008).
To fully induce hTERT expression and telomerase activity in
keratinocytes, HPV E6/E6AP requires expression of NFX1–123, the
other splice variant of NFX1, (Katzenellenbogen et al., 2007) (Fig. 4).
Unlike NFX1–91, NFX1–123 augments hTERT promoter driven
expression by HPV E6/E6AP (Katzenellenbogen et al., 2007). NFX1–
123 interacts with cytoplasmic poly(A) binding proteins, which bind
to the poly(A) tail of mRNA and increase protein expression through
nuclear-to-cytoplasmic transcript shuttling, translational machinery
recruitment, and mRNA stabilization (for review see Kuhn andWahle,
2004). The PAM2 of NFX1–123 is required for the interaction with
cytoplasmic poly(A) binding proteins, and this motif is critical for the
increase in hTERT expression when NFX1–123 is overexpressed in E6
expressing keratinocytes (Katzenellenbogen et al., 2007). This inter-
action between HPV E6/E6AP, NFX1–123, and cytoplasmic poly(A)
binding proteins, hints at additional evidence of hTERT regulation
beyond transcriptional regulation (Anderson et al., 2006; Cerezo et al.,
2002; Emerald et al., 2007; Fujiwara et al., 2004).
Mediating chromosome stability
In addition to increasing the expression of hTERT, E6 also
interacts with other proteins involved in maintaining chromosomal
stability within the HPV infected cell. First, E6 from both HR and LR
HPVs have been shown to interact with the human minichromosome
maintenance 7 (hMCM7) protein, although binding by HR E6
proteins appears to be stronger than that by LR E6 proteins
(Kukimoto et al., 1998). Moreover, 18E6 was shown to mediate
MCM7 degradation via E6AP and proteasomal involvement (Kuhne
331Minireviewand Banks, 1998). As MCM7 is involved in licensing DNA replication
to ensure a single round of DNA replication per cell cycle, it is
thought that E6 interaction with and/or degradation of MCM7 may
lead to chromosomal abnormalities in HPV infected cells. E6 has also
been shown to interact with two proteins involved in single strand
DNA break repair — XRCC1 and O(6)-methylguanine-DNA methyl-
transferase (MGMT) (Iftner et al., 2002; Srivenugopal and Ali-Osman,
2002). XRCC1 was shown to be bound by HPV 1, 8 and 16E6, and this
interaction reduced the ability of XRCC1 to repair methyl methane
sulfate (MMS) induced DNA damage (Iftner et al., 2002). E6
interaction with MGMT induces its proteasomal-mediated degrada-
tion via E6AP, which has been hypothesized to sensitize HPV-
infected cells to alkylating DNA damage (Srivenugopal and Ali-
Osman, 2002). Finally, HR E6 mediated p53 loss inactivates the G1
checkpoint. Prolonged proliferation in the absence of p53 can lead to
the loss of the G2 checkpoint, which can result in aneuploidy
(Passalaris et al., 1999). Together, these interactions may lead to
increased genomic instability and accelerate the progression to
carcinogenesis.
Disrupting cell adhesion, polarity and epithelial differentiation
Basal cells of squamous epithelium attach to the extracellular
matrix (ECM) of the basement membrane and receive signals allowing
their proliferation. Once daughter cells detach from the basement
membrane and migrate to suprabasal layers, proliferative signals
cease and markers of epithelial differentiation are expressed. The
establishment of cell:ECM adhesion, cell:cell contact, cytoskeletal
organization and apicobasal polarity of epithelial cells is tightly
regulated to assure regulated proliferation and differentiation (Bilder,
2004). E6 proteins, particularly of HR HPVs, disrupt many of these
processes to allow proliferation of differentiated cells and inhibition of
terminal differentiation to support viral replication.
Both paxillin and zyxin are focal adhesion molecules that are
involved in tethering the cellular cytoskeleton to the ECM and
transmitting signals along the actin network from the ECM to the
nucleus. E6 from diverse papillomaviruses have been shown to bind to
these proteins (Degenhardt and Silverstein, 2001a; Tong and Howley,
1997) resulting in the disruption of actin ﬁbers and a failure to
maintain proper cell structure.
hScrib, a PDZ domain containing protein, is also involved in
epithelial tight junctions, mediating the adhesion of basal cells to the
ECM. It functions as a tumor suppressor that negatively regulates
proliferation. HR HPV E6 proteins bind to hScrib, and at least in some
cell types have been shown to mediate its degradation (Nakagawa and
Huibregtse, 2000). Similarly, hDlg is a PDZ domain containing protein
involved in epithelial tight junctions, cell:cell junctions and epithelial
polarity, functioning as a tumor suppressor. hDlg was the ﬁrst PDZ
protein shown to bind to HR E6 proteins (Kiyono et al., 1997; Lee et al.,
1997). The MAGI proteins and MUPP1 also play a role in maintaining
epithelial cell junctions, negatively regulating cell proliferation and in
signal transduction from the cell membrane. Likewise they bind HR
HPV E6 proteins and disrupt regulation of epithelial proliferation
(Glaunsinger et al., 2000; Thomas et al., 2002). Recently it has been
shown that PTPN3, a membrane-bound tyrosine phosphatase that
regulates growth factor receptors is also a PDZ protein that binds and
is disrupted by E6 (Jing et al., 2007; Spanos et al., 2008a).
Whether HR HPV E6 proteins bind and target all those PDZ
proteins for degradation in vivo is controversial. When the HPV 31
genome was transfected into keratinocytes Western analysis did not
reveal any signiﬁcant changes in the levels of PDZ proteins and in
organotypic raft cultures, immunohistochemical analysis failed to
identify substantial changes in the differentiation-dependent mem-
brane localization of hDlg proteins (Lee and Laimins, 2004). Instead,
deletion or mutation of PDZ domain-binding motif of E6 impaired the
growth rate of cell lines harboring the mutant genomes and reducedthe viral copy number compared to cells transfected with wild-type
genomes. The results suggested that binding of E6 to PDZ proteins
modulates the early viral functions such as proliferation and
maintenance of the viral copy number in undifferentiated cells.
Additionally, studies that have investigated the mechanism of
degradation of the PDZ proteins in-vitro have reached opposite
conclusions as to whether E6AP is the ubiquitin ligase that promotes
proteosomal degradation (Grm and Banks, 2004; Sterlinko et al.,
2004).
Conclusions
The small DNA tumor viruses have provided valuable tools for
understanding fundamental processes involved in cellular replication
and tumorigenesis. They encode only a small number of genes, which
are able to subvert the controls that regulate proliferation, contribut-
ing both acutely to transformation and by initiating genetic instability.
The E6 protein of papillomaviruses targets numerous cellular path-
ways to insure viral DNA replication and is a key oncogene in HPV
associated neoplasias. E6 from the high risk HPVs has been shown to
inactivate p53, block apoptosis, activate telomerase, disrupt cell
adhesion, polarity and epithelial differentiation, alter transcription
and G-protein signaling, and reduce immune recognition of HPV
infected cells. The pathways that are targeted by E6 in HPV associated
cancers have provided important insights to identify the critical
mutations that are commonly found in other tumors.References
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